Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 3/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
| ▸ | ACACA | Q13085 | 1/20 | 0.39 |
| ▸ | KHK | P50053 | 4/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.37 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.37 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.37 |
| ▸ | SMO | Q99835 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4912896 | 1.00 | GBA1 (0.39) | GBA1CXCR3ACACBACACAKHK | |
| SCHEMBL4913559 | 0.92 | KHK (0.40) | GBA1ACACBACACAKHKKDM4E | |
| SCHEMBL4913546 | 0.92 | KHK (0.40) | GBA1ACACBACACAKHKKDM4E | |
| SCHEMBL14294581 | 0.91 | CXCR3 (0.49) | CXCR3 | |
| SCHEMBL14294584 | 0.91 | CXCR3 (0.49) | CXCR3 | |
| SCHEMBL14270929 | 0.91 | CXCR3 (0.49) | CXCR3 | |
| SCHEMBL14270933 | 0.91 | CXCR3 (0.49) | CXCR3 | |
| SCHEMBL4917981 | 0.88 | SGPL1 (0.46) | ACACBACACAKHKMAPT | |
| SCHEMBL4915924 | 0.88 | SGPL1 (0.46) | ACACBACACAKHKMAPT | |
| SCHEMBL907725 | 0.87 | SYK (0.42) | CXCR3KHKKDM4ESMOSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045525-A1 | Piperazinyl-Pyridine Analogues | NEUROGEN CORPORATION | 2008-02-21 | — | — | US | claimed |
| CN-101080228-A | Piperazinyl-pyridine analogues | NEUROGEN CORP (US) | 2007-11-28 | — | — | CN | claimed |
| US-20080045525-A1 | Piperazinyl-Pyridine Analogues | NEUROGEN CORPORATION | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045525-A1 | Piperazinyl-Pyridine Analogues | PRLHR, GPR27, GPR68 | GBA1 1820/4885CXCR3 1017/4885ACACB 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.